Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Video

In Partnership With:

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD